Pneumococcal conjugate vaccines in infants and children under 5 years of age

WHO Position paper
Pneumococcal disease
Multiple regions
Original Title
Pneumococcal conjugate vaccines in infants and children under 5 years of age
Author
SAGE
Topics
recommendation
Sources
WHO/WER Weekly Epidemiological Record
Publication Year
2019

Abstract

A 23-valent polysaccharide vaccine has been available since the early 1980s, and pneumococcal conjugate vaccines (PCV) have been available since 2009. The focus of this position paper is use of PCV in infants and children <5 years of age; a separate position paper on vaccination of older age groups with conjugate and polysaccharide vaccines will be developed after consideration by SAGE. The present position paper includes data on the effects of the 10- and 13-valent PCVs (PCV10 and PCV13) published up to June 2017 and specifically addresses the dosing schedule, product choice and the value of catch-up vaccination in children under 5 years of age.
Recommendations on the use of PCVs were discussed by SAGE in October 2017. Evidence presented at the meeting can be accessed at: http://www.who.int/immunization/sage/meetings/2017/october/presentations_background_docs/en/.

Related News & Events

  • Chile
    Functioning

    Chile's NITAG documents the results of the committee's evaluation

    02.07.2019

    In this article, we describe the structure, functioning and work processes of Chile’s NITAG (CAVEI) and assess its functionality, quality of work processes and outputs, and integration of the committee into the Ministry of Health policy process using the Assessment tool for National Immunization Technical Advisory Groups.

    Read more
  • NITAG training

    Read more on NITAG training in resource-constrained settings

    20.06.2019

    Antoinette Ba-Nguy and Adeel Shaah, ex-SIVAC staff and experienced NITAG trainers,  wrote an article on the NITAG trainings delivered through the Partnership for Influenza Vaccine Introduction (PIVI) program.

    Read more
  • SAGE

    new Interim Recommendations on Vaccination against Ebola Virus Disease from SAGE

    13.05.2019

    Over the last four weeks, the Ebola outbreak in the Eastern Provinces of the Democratic Republic of Congo (DRC) has deteriorated with a large increase in the number of cases1. A major factor in this rise is an increase in critical security incidents that have dramatically affected the ability to identify, follow up and vaccinate contacts successfully. This context challenges the implementation of ring vaccination based on the identification of contacts and contacts of contacts, as recommended by SAGE in April 2017 and confirmed by SAGE during its April 2019 meeting. Further, a potential vaccine shortage may manifest in case the outbreak expands further and/or is prolonged.

    Read more